Synthesis, Evaluation of Antiangiogenic Activity of Novel Coumarinyl 4-Thiazolidinone Derivatives

Cancer remains in the maximum percentage probability of death in spite of the latest advancement in prior diagnosis and different approaches to treatment. The major challenge in drug discovery for medicinal chemists is to develop new cytotoxic agents to cure cancer with fewer side effects. A new series of substituted coumarinyl 4-thiazolidinone derivatives (TZL1–TZL7) were prepared by treating different 4-hydroxy-3-(1-(phenylimino0ethyl)-2H-chromen-2-one with HSCH2COOH. The Schiff bases were obtained by treating 4-hydroxy coumarin with different aniline derivatives in the presence of C2H5OH. All the title compounds were purified and subjected to TLC to check their purity. Further, it was characterized by using IR,¹H-NMR, and mass spectral studies. Selected synthesized compounds (TZL1–TZL7) were screened for in-vivo antiangiogenic activity by using the Zebrafish model. TZL2 had the best antiangiogenic effect with an average vein count of 2.7. TZL4, TZL5, and TZL6 had an average vein count of 4.1, 3.9, and 3.4, respectively.